Department of Medical and Surgical Sciences, Clinica Medica, University of Padua, Italy.
J Endocrinol Invest. 2010 May;33(5):347-52. doi: 10.1007/BF03346598.
The occurrence of metabolic bone disease in patients with renal dysfunction is due to the key role played by the kidney in regulating calcium-phosphate metabolism. The incidence of hip fractures in end-stage renal disease is 3- to 4-fold higher than the general population, while poor data about vertebral fractures show similar prevalence. Bone health has been mainly evaluated in the general population through bone mass density (BMD) measurements, while in Chronic Kidney Disease (CKD) patients, bone turnover (low or high turnover) has been considered the most relevant parameter. Indeed, in CKD patients, the association between BMD and fractures is unclear, and even studies on established risk factors (body mass index, PTH, and vitamin D) for fractures have contrasting outcomes. Recently, an important association has been found between bone disorders and vascular calcifications in CKD patients that has changed the denomination of renal osteodystrophy in CKD mineral and bone disorder. In this article, a poorly investigated subject, vertebral fractures in CKD patients, is addressed, as it is underestimated despite its remarkable clinical relevance.
肾功能障碍患者发生代谢性骨病是由于肾脏在调节钙磷代谢中起着关键作用。终末期肾病患者髋部骨折的发生率比普通人群高 3 到 4 倍,而关于椎体骨折的数据较差,表明其患病率相似。骨骼健康主要通过骨密度 (BMD) 测量在普通人群中进行评估,而在慢性肾脏病 (CKD) 患者中,骨转换 (低转换或高转换) 被认为是最相关的参数。事实上,在 CKD 患者中,BMD 与骨折之间的关系并不明确,甚至对骨折的既定危险因素(体重指数、PTH 和维生素 D)的研究也得出了相互矛盾的结果。最近,在 CKD 患者中发现了骨骼疾病与血管钙化之间的重要关联,这改变了 CKD 矿物质和骨代谢紊乱中肾性骨营养不良的命名。本文探讨了 CKD 患者椎体骨折这一研究甚少的课题,尽管其具有显著的临床意义,但仍未得到充分重视。